Amili Pte Ltd

AMILI (Amili Pte Ltd) is a Singapore-headquartered microbiome science company that describes itself as one of the leading microbiome companies in Asia. It was founded in 2019 and is built around what it calls the world's largest multi-ethnic Asian gut microbiome database. The company's stated mission is to translate microbiome science into personalised, clinically-informed solutions that support gut and overall health, with a particular emphasis on science developed for Asian populations rather than Western datasets. AMILI's consumer-facing offering centres on an at-home Gut Health Test Kit, priced from S$400, which analyses a stool sample and returns a report with more than 20 insights, including a microbiome age benchmarked against healthy Asian populations, functional scores covering the gut-brain axis, immunity and metabolism, and digestion, plus personalised dietary recommendations. The company also sells a range of targeted probiotic formulations designed for the Asian gut, addressing areas such as metabolic health, immune-metabolic health, complete health, brain and cognitive health, and digestive health, with prices starting around S$60 to S$90. Subscription plans are offered to encourage repeat purchase. Beyond single products, AMILI markets structured programs. The AMILI Optimise Plus program is an eight-week microbiome program that pairs a gut microbiome test with continuous glucose monitoring and a personalised nutrition plan, priced at S$750. The company also offers nutrition and lifestyle coaching. In 2023 AMILI introduced analytics-as-a-service, positioning itself as a "brand behind the brands" by supplying microbiome analytics to other companies, and in 2024 it began prototyping microbial test kits for colorectal cancer. A 2025 partnership with A*STAR aims to personalise nutrition with the gut as the cornerstone, with a diet-as-a-service offering planned for 2026. AMILI was founded by a group of medical and scientific leaders: Dr. Jeremy Lim serves as CEO and co-founder, Dr. Christopher Ting as co-founder and vice-chairman, and Dr. Jonathan Lee and Dr. David Ong as co-founders. Dr. David Ong performed the first microbiome restoration therapy (MRT) in Singapore in 2014, an event AMILI traces as a research origin. The leadership team also includes Manu Swarup as chief operating officer and Jit Han Tan as chief growth officer, supported by a panel of clinical advisors. The company raised a US$10.5 million Series A round in 2022. AMILI remains a private company and operates primarily in Singapore and the wider Southeast Asian and Asian markets.

AMILI's history is presented by the company as a journey from research origins to regional impact. The earliest milestone it cites is 2014, when Dr. David Ong, who would become an AMILI co-founder, performed the first microbiome restoration therapy (MRT) in Singapore. That clinical work laid the scientific foundation on which the company was later built. AMILI itself was founded in 2019 in Singapore. The following year, 2020, the company launched what it describes as Southeast Asia's first gut health test and MRT service, bringing microbiome analysis to consumers in the region. In 2021 AMILI expanded into products with the launch of targeted probiotics formulated for the multi-ethnic Asian gut, moving beyond testing into ongoing gut health support. In 2022 the company raised a US$10.5 million Series A round, providing capital to scale its consumer and clinical offerings. In 2023 AMILI introduced analytics-as-a-service, a business-to-business offering that positioned the company as a "brand behind the brands" — supplying microbiome analytics and capabilities to other companies rather than only selling directly to consumers. In 2024 the company began prototyping microbial test kits for colorectal cancer, extending its technology toward oncology screening. In 2025 AMILI announced a partnership with A*STAR to personalise nutrition with the gut as the cornerstone, and stated that a diet-as-a-service offering would follow in 2026. Throughout its development, AMILI has emphasised its multi-ethnic Asian gut microbiome database as a core asset, arguing that microbiome science built on Asian data is more relevant to Asian populations than Western datasets. The company remains privately held and Singapore-headquartered, selling its tests, probiotics and programs primarily in Singapore and the wider Asian market.

• 2025

  A*STAR partnership to personalise nutrition with the gut as the cornerstone; diet-as-a-service offering in 2026

• 2024

  Prototyping of microbial test kits for colorectal cancer

• 2023

  Introduced analytics-as-a-service; brand behind the brands

• 2022

  Raised US$10.5M Series A

• 2021

  Launched targeted probiotics for multi-ethnic Asia

• 2020

  Launched first Southeast Asia's gut health test and MRT service

• 2019

  Founding of AMILI

• 2014

  First Microbiome Restoration Therapy (MRT) in Singapore performed by Dr. David Ong, AMILI Co-Founder

Clinically-informed, Asia-focused microbiome science translated into personalised gut health products and services.

• Gut Health Test Kit

  At-home gut microbiome test priced from S$400, delivering over 20 insights including microbiome age and functional scores.

• AMILI Optimise Plus

  An 8-week program combining gut microbiome testing and continuous glucose monitoring to build a personalised nutrition and lifestyle plan, priced at S$750.

• Targeted probiotics

  Probiotic formulations for the Asian gut covering metabolic health, immune-metabolic health, complete health, brain and cognitive health, and digestive health, from about S$60–S$90.

• Nutrition & Lifestyle Coaching

  Coaching service supporting gut health goals.

• Analytics-as-a-service

  B2B microbiome analytics offering introduced in 2023.

1. 1Gut Microbiome Testing & Probiotics for Asia | AMILIamili.asia
2. 2About AMILI: Asia's Gut Microbiome Companyamili.asia
3. 3Shop Gut Microbiome Tests & Probiotics | AMILIamili.asia
4. 4Gut Health Test Kit | AMILIamili.asia
5. 5Amili Pte Ltd (Singapore)wikidata.org